Chapter 28
Plasma Cell Disorders
Bill G. Richendollar MD, James R. Cook MD, PhD,
James R. Cook MD, PhD
Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, USA
Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA
Search for more papers by this authorBill G. Richendollar MD, James R. Cook MD, PhD,
James R. Cook MD, PhD
Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, USA
Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA
Search for more papers by this authorBook Editor(s):Kandice Kottke-Marchant MD, PhD,
Bruce H. Davis MD,
Kandice Kottke-Marchant MD, PhD
Pathology & Laboratory Medicine Institute, Cleveland, OH, USA
Department of Pathology, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA
Hemostasis and Thrombosis, Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH, USA
Search for more papers by this authorFirst published: 10 April 2012
Summary
The plasma cell disorders are a heterogeneous group of clonal plasma cell proliferations with clinical presentations that range from a completely asymptomatic laboratory finding to a highly aggressive malignant neoplasm. The correct diagnosis and classification of these diseases requires correlation of the bone marrow morphologic findings with the clinical features and results of other laboratory tests. Increasingly, molecular cytogenetic characterization is also an important aspect of the workup of plasma cell disorders. This chapter summarizes the approach to the diagnosis and classification of the major plasma cell disorders including plasma cell myeloma, monoclonal gammopathy of undetermined significance, plasma cell leukemia, and primary amyloidosis.
References
- Malpas J, Bergsagel PL, Kyle R et al. (eds.) Myeloma: Biology and Management. Philadelphia, PA, Saunders; 2004.
- McKenna RW, Kyle R, Kuehl WM et al. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL et al. WHO classification of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2008; 200–213.
- Fonseca R, Barlogie B, Bataille R et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64: 1546–1558.
- Fonseca R. Strategies for risk-adapted therapy in myeloma. Hematology Am Soc Hematol Educ Program 2007; 304–310.
- Fonseca R, San Miguel J. Prognostic factors and staging in multiple myeloma. Hematol Oncol Clin North Am 2007; 21: 1115 – 1140; ix.
- Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology Am Soc Hematol Educ Program 2005; 346–352.
- Liebisch P, Dohner H. Cytogenetics and molecular cytogenetics in multiple myeloma. Eur J Cancer 2006; 42: 1520–1529.
- Zhan F, Huang Y, Colla S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020–2028.
- Attaelmannan M, Levinson SS. Understanding and identifying monoclonal gammopathies. Clin Chem 2000; 46: 1230–1238.
- Dispenzieri A, Kyle R, Merlini G et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215–224.
- Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol 2008; 141: 413–422.
- Nowakowski GS, Witzig TE, Dingli D et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005; 106: 2276–2279.
- Bartl R, Frisch B, Fateh-Moghadam A et al. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol 1987; 87: 342–355.
- Greipp PR, Raymond NM, Kyle RA et al. Multiple myeloma. significance of plasmablastic subtype in morphological classification. Blood 1985; 65: 305–310.
- Rawstron AC, Orfao A, Beksac M et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008; 93: 431–438.
- Smock KJ, Perkins SL, Bahler DW. Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment. Arch Pathol Lab Med 2007; 131: 951–955.
- DiGiuseppe JA. Flow cytometric immunophenotyping of plasmacytic neoplasms. Am J Clin Pathol 2007; 127: 172–174.
- Seegmiller AC, Xu Y, McKenna RW et al. Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma. Am J Clin Pathol 2007; 127: 176–181.
- Lin P, Owens R, Tricot G et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004; 121: 482–488.
- Al-Quran SZ, Yang L, Magill JM et al. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry. Hum Pathol 2007; 38: 1779–1787.
- Ng AP, Wei A, Bhurani D et al. The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells. Haematologica 2006; 91: 972–975.
- Avet-Loiseau H. Role of genetics in prognostication in myeloma. Best Pract Res Clin Haematol 2007; 20: 625–635.
- Lin P. Plasma cell myeloma. Hematol Oncol Clin North Am 2009; 23: 709–727.
- Robillard N, Avet-Loiseau H, Garand R et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 2003; 102: 1070–1071.
- Cook JR, Hsi ED, Worley S et al. Immunohistochemistry Identifies Two Cyclin D1 Positive Subsets of Plasma Cell Myeloma, Each Associated With Favorable Survival. Am J Clin Pathol 2006; 125: 615–624.
- Sahara N, Ohnishi K, Ono T et al. Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma. Eur J Haematol 2006; 77: 14–18.
- Bataille R, Pellat-Deceunynck C, Robillard N et al. CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. Leuk Res 2008; 32: 379–382.
- Troussard X, Avet-Loiseau H, Macro M et al. Cyclin D1 expression in patients with multiple myeloma. Hematol J 2000; 1: 181–185.
- Soverini S, Cavo M, Cellini C et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood 2003; 102: 1588–1594.
- Chang H, Stewart AK, Qi XY et al. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 2005; 106: 353–355.
- Larson A, Cook JR. Fibroblast Growth Factor Receptor 3 (FGFR3) Expression in Malignant Lymphomas. Appl Immunohistochem Mol Morphol 2008; 16: 322–325.
- Chang H, Yeung J, Qi C et al. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma. Br J Haematol 2007; 138: 324–329.
- Magrangeas F, Lode L, Wuilleme S et al. Genetic heterogeneity in multiple myeloma. Leukemia 2005; 19: 191–194.
- Fonseca R, Debes-Marun CS, Picken EB et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003; 102: 2562–2567.
- Gertz MA, Lacy MQ, Dispenzieri A et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837–2840.
- Moreau P, Facon T, Leleu X et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100: 1579–83.
- Drach J, Ackermann J, Fritz E et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998; 92: 802–809.
- Chiecchio L, Protheroe RK, Ibrahim AH et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006; 20: 1610–1617.
- Dispenzieri A, Rajkumar SV, Gertz MA et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007; 82: 323–341.
- Kyle RA, Therneau TM, Rajkumar SV et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362–1369.
- Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol 2006; 134: 573–589.
- Fonseca R, Bailey RJ, Ahmann GJ et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100: 1417–1424.
- Jimenez-Zepeda VH, Dominguez-Martinez VJ. Plasma cell leukemia. a highly aggressive monoclonal gammopathy with a very poor prognosis. Int J Hematol 2009; 89: 259–268.
- Garcia-Sanz R, Orfao A, Gonzalez M et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999; 93: 1032–1037.
- Pellat-Deceunynck C, Barille S, Jego G et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 1998; 12: 1977–1982.
- Tiedemann RE, Gonzalez-Paz N, Kyle RA et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008; 22: 1044–1052.
- Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis: diagnosis and management. Clin Lymphoma Myeloma 2005; 6: 208–219.
- Comenzo RL. Systemic immunoglobulin light-chain amyloidosis. Clin Lymphoma Myeloma 2006; 7: 182–185.
- Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 2006; 81: 693–703.
- Kebbel A, Rocken C. Immunohistochemical classification of amyloid in surgical pathology revisited. Am J Surg Pathol 2006; 30: 673–683.
- Grasso G. The use of mass spectrometry to study amyloid β peptides. Mass Spectrom Rev. 2011; 30: 347–365.
- Bochtler T, Hegenbart U, Cremer FW et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood 2008; 111: 4700–4705.
- Bryce AH, Ketterling RP, Gertz MA et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica 2009; 94: 380–386.
- Buxbaum J, Gallo G. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light-and heavy-chain deposition diseases. Hematol Oncol Clin North Am 1999; 13: 1235–1248.
